Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neurogene (NGNE) Cash from Operations (2018 - 2025)

Neurogene's Cash from Operations history spans 6 years, with the latest figure at 17500000.0 for Q4 2025.

  • For Q4 2025, Cash from Operations changed 0.02% year-over-year to 17500000.0; the TTM value through Dec 2025 reached 77200000.0, down 9.34%, while the annual FY2025 figure was 77200000.0, 9.34% down from the prior year.
  • Cash from Operations reached 17500000.0 in Q4 2025 per NGNE's latest filing, up from 19464000.0 in the prior quarter.
  • In the past five years, Cash from Operations ranged from a high of 9327000.0 in Q2 2023 to a low of 21700000.0 in Q1 2024.
  • Average Cash from Operations over 3 years is 16600250.0, with a median of 17198000.0 recorded in 2023.
  • Peak YoY movement for Cash from Operations: tumbled 69.4% in 2024, then grew 4.15% in 2025.
  • A 3-year view of Cash from Operations shows it stood at 16900000.0 in 2023, then dropped by 3.53% to 17496000.0 in 2024, then dropped by 0.02% to 17500000.0 in 2025.
  • Per Business Quant, the three most recent readings for NGNE's Cash from Operations are 17500000.0 (Q4 2025), 19464000.0 (Q3 2025), and 19436000.0 (Q2 2025).